Living Cell Technologies maps timeline to clinical results from Parkinson's trial
Wednesday, 8 November 2017 () Living Cell Technologies Ltd (ASX:LCT) is preparing some highly anticipated results from the NTCELL Parkinson's disease clinical trial, which are expected on Friday 10th November 2017. Shares in the company had been rising on the anticipation, recently hitting $0.28, but have lost some momentum and were changing hands at $0.205 at yesterday's close. Mid-year shares could have been snapped up around the $0.11 range. The ASX has this morning granted Living Cell a trading halt to prepare details from the trial. The halt will remain in place until the opening of trade on Monday 13th November 2017, or earlier if an announcement is made to the market.
Drug discovery company Summit Therapeutics PLC (LON:SUMM) (NASDAQ: is set to present pre-clinical data from the University of Oxford highlighting the potential... Proactive Investors - BusinessAlso reported by •Business Wire